3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Lymphoid
1
Conditions
Squamous Cell Carcinoma of Head and Neck
4
Neoplasms
3
Neoplasms by Site
2
Neoplasms by Histologic Type
2
Neoplasm Metastasis
2
Leukemia, Myeloid, Acute
2
Carcinoma, Squamous Cell
2
Carcinoma, Non-Small-Cell Lung
2
Carcinoma
2
Vascular Diseases
1
Thoracic Neoplasms
1
Respiratory Tract Neoplasms
1
Respiratory Tract Diseases
1
Recurrence
1
Pathologic Processes
1
Paraproteinemias
1
Pancreatic Neoplasms
1
Oropharyngeal Neoplasms
1
Neoplastic Processes
1
Neoplasms, Plasma Cell
1
Neoplasms, Glandular and Epithelial
1
Multiple Myeloma
1
Mouth Neoplasms
1
Lymphoproliferative Disorders
1
Lymphoma
1
Lymphoid Interstitial Pneumonia
1
Lymphatic Diseases
1
Lung Neoplasms
1
Lung Diseases
1
Liver Neoplasms
1
Interventions
Cholecalciferol
4
Nutrition Assessment
3
Exercise
3
Blood Pressure
3
Atorvastatin
3
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
2
Vitamin E
2
Vitamin D
2
Rosuvastatin Calcium
2
Methods
2
Metformin
2
Gonadotropin-Releasing Hormone
2
Geritol
2
Fish Oils
2
Fatty Acids, Omega-3
2
Ethanol
2
Educational Status
2
Diet, Mediterranean
2
Aspirin
2
xinmailong
1
sofosbuvir-velpatasvir drug combination
1
pembrolizumab
1
palbociclib
1
ficlatuzumab
1
beta Carotene
1
amlodipine, atorvastatin drug combination
1
Vorinostat
1
Vitamin B 6
1
Vitamin B 12
1
Tumor Necrosis Factor Inhibitors
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Cardiovascular Diseases
×
ficlatuzumab
×
Clear all
NCT00725634
2014-01-27
P05538
AVEO Pharmaceuticals, Inc.
Phase 1
Completed
41 enrolled